

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[← Back](#)

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

[Patient & Family Resources](#)

[Refer a Patient](#)

## The Emily Cheng Lab

### ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)


[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

-----




Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

---

The focus of the Cheng laboratory is to elucidate the molecular mechanisms of cell death with an overarching goal of directly translating cell death mechanisms into novel anti-cancer therapeutic strategies that can effectively trigger cancer cell death and enhance anti-cancer immunity.

[View Lab Overview](#) →



The Cheng Lab

## Publications Highlights

[Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022 Feb 3. doi: 10.1038/s43018-021-00316-3. Epub ahead of print.](#)

[Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 Sep 13;39\(9\):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. PMID: PMC8440494.](#)

[Ren D, Tu H, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010 Dec 3;330\(6009\):1390-3. doi: 10.1126/science.1190217.](#)

[Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J, Zambetti GP, Hsieh JJD, Cheng EHY. Hierarchical regulation of](#)


[mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006 Dec;8\(12\):1348-58. Epub 2006 Nov 19.](#)

---

[Kim H, Tu H, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009 Nov 13;36\(3\):487-99. doi: 10.1016/j.molcel.2009.09.030.](#)

[View All Publications](#)

## People



## Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program


Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.

MD, Taipei Medical University

PhD, Johns Hopkins University School of Medicine

 [cheng1@mskcc.org](mailto:cheng1@mskcc.org)

Email Address

 [646-888-3258](tel:646-888-3258)

Office Phone

## Members

Lab Alumni

+

Lab Affiliations

+

## Achievements

Distinguished Investigator Award, Washington University School of Medicine (2010)

Searle Scholar Award (2005)

Howard Temin Award, National Cancer Institute (2003)

## Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

---

## Career Opportunities

[Apply now](#) →

## Get in Touch

✉ [cheng1@mskcc.org](mailto:cheng1@mskcc.org)

Lab Head Email

☎ [646-888-3258](tel:646-888-3258)

Office Phone

☎ [646-888-3266](tel:646-888-3266)

Office Fax

## Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Emily H. Cheng discloses the following relationships and financial interests:

*No disclosures meeting criteria for time period*

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure

submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures](#) →






▼ Connect

[Contact us](#)

[Locations](#)


APPOINTMENTS


[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)


[Integrative medicine](#)

[Nutrition & cancer](#)


[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

---

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center